These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 3140865)

  • 1. 'Perming' effects associated with chronic valproate therapy.
    Gupta AK
    Br J Clin Pract; 1988 Feb; 42(2):75-7. PubMed ID: 3140865
    [No Abstract]   [Full Text] [Related]  

  • 2. [Valproic acid, curly hair and weight gain].
    Bittencourt PR
    Arq Neuropsiquiatr; 1986 Mar; 44(1):78-81. PubMed ID: 3090984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuropsychiatric symptoms caused by valproic acid].
    Andrade R; García-Espinosa A; Pérez-Montoto A; Toledo-Sotomayor G; Remón-González Y; Frades-García V
    Rev Neurol; 2010 Jan 1-15; 50(1):62-3. PubMed ID: 20073028
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver.
    Alqahtani S; Federico P; Myers RP
    CMAJ; 2007 Sep; 177(6):568-9. PubMed ID: 17846437
    [No Abstract]   [Full Text] [Related]  

  • 5. Generalized edema with risperidone: divalproex sodium treatment.
    Baldassano CF; Ghaemi SN
    J Clin Psychiatry; 1996 Sep; 57(9):422. PubMed ID: 9746451
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of surgical blood loss and number of blood transfusions after temporal lobe resection performed in adults with epilepsy receiving valproate (VPA) in the immediate preoperative period.
    Gil-Fernández JJ
    Epilepsia; 1997 Nov; 38(11):1257-8. PubMed ID: 9579931
    [No Abstract]   [Full Text] [Related]  

  • 7. [Valproic acid -- clinical efficiency and serum concentration in the treatment of petit mal epilepsy in childhood (author's transl)].
    Fritsch G; Haidvogl M; Gleispach H; Ladurner G
    Padiatr Padol; 1981; 16(4):481-8. PubMed ID: 6795573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hyperammonemic coma with chronic valproic acid therapy.
    Cuturic M; Abramson RK
    Ann Pharmacother; 2005 Dec; 39(12):2119-23. PubMed ID: 16288075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of valproate in porphyria.
    Garcia-Merino JA; Lopez-Lozano JJ
    Lancet; 1980 Oct; 2(8199):856. PubMed ID: 6107519
    [No Abstract]   [Full Text] [Related]  

  • 10. [Laboratory parameters in valproate therapy].
    Schneble H
    Nervenarzt; 1982 Dec; 53(12):684-90. PubMed ID: 6818481
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of hyperammonemia in stuporous states induced by sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
    Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovary syndrome associated with treatment with the anticonvulsant sodium valproate.
    Sharma S; Jacobs HS
    Curr Opin Obstet Gynecol; 1997 Dec; 9(6):391-2. PubMed ID: 9425584
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sodium valproate (Na VPa) monotherapy in childhood epilepsy ].
    Dulac O; Steru D; Rey E; Arthuis M
    Arch Fr Pediatr; 1982; 39(6):347-52. PubMed ID: 6812534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium valproate in pregnancy.
    Cairney P; Hornabrook RW; Ainsworth JW
    N Z Med J; 1981 Sep; 94(692):238. PubMed ID: 6795550
    [No Abstract]   [Full Text] [Related]  

  • 15. Valproate-associated coagulopathies are frequent and variable in children.
    Attilakos A; Katsarou E; Voudris K; Garoufi A
    Epilepsia; 2007 Jan; 48(1):205-6. PubMed ID: 17241231
    [No Abstract]   [Full Text] [Related]  

  • 16. Valproate-induced coma with ketosis and carnitine insufficiency.
    Triggs WJ; Bohan TP; Lin SN; Willmore LJ
    Arch Neurol; 1990 Oct; 47(10):1131-3. PubMed ID: 2121122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of sodium valproate in partial epilepsy. Crossed study of valproate and carbamazepine].
    Loiseau P; Cohadon S; Jogeix M; Legroux M; Dartigues JF
    Rev Neurol (Paris); 1984; 140(6-7):434-7. PubMed ID: 6431586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium valproate reassessed.
    Drug Ther Bull; 1981 Nov; 19(24):93-5. PubMed ID: 6793342
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensorineural hearing loss: a reversible effect of valproic acid.
    Armon C; Brown E; Carwile S; Miller P; Shin C
    Neurology; 1990 Dec; 40(12):1896-8. PubMed ID: 2247241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible dementia and apparent brain atrophy during valproate therapy.
    Papazian O; Cañizales E; Alfonso I; Archila R; Duchowny M; Aicardi J
    Ann Neurol; 1995 Oct; 38(4):687-91. PubMed ID: 7574471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.